Who are Kanacin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Netromycin, Arikayce Kit, Garamycin, Cortisporin, loteprednol etabonate and tobramycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/kanamycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Kanacin — Competitive Intelligence Brief

Kanacin (KANAMYCIN) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aminoglycoside Antibacterial. Area: Metabolic.

marketed Aminoglycoside Antibacterial Gap junction beta-2 protein Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Kanacin (KANAMYCIN) — Bristol-Myers Squibb.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Kanacin TARGET	KANAMYCIN	Bristol-Myers Squibb	marketed	Aminoglycoside Antibacterial	Gap junction beta-2 protein	1973-01-01
Netromycin	NETILMICIN		marketed	Aminoglycoside Antibacterial		1983-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	marketed	Aminoglycoside Antibacterial		1981-01-01
Garamycin	GENTAMICIN	Merck & Co.	marketed	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Cortisporin	NEOMYCIN	Pfizer	marketed	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 1	1957-01-01
loteprednol etabonate and tobramycin	loteprednol etabonate and tobramycin	Bausch & Lomb Incorporated	marketed	Aminoglycoside Antibacterial [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aminoglycoside Antibacterial class)

Bristol-Myers Squibb · 2 drugs in this class
· 1 drug in this class
Merck & Co. · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kanacin — Competitive Intelligence Brief. https://druglandscape.com/ci/kanamycin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab